• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by iRhythm Technologies Inc.

    8/5/25 4:51:34 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001209186
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    IRHYTHM TECHNOLOGIES, INC.
    SEC File Number
    001-37918
    Address of Issuer
    699 8th Street
    Suite 600
    San Francisco
    CALIFORNIA
    94103
    Phone
    (415) 632-5700
    Name of Person for Whose Account the Securities are To Be Sold
    MARK JEFFREY RUBASH
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    150002408109.003212776308/05/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common08/05/2025Stock Option ExerciseIssuerCheckbox not checked1500008/05/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    08/05/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    05/05/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Mark Jeffrey Rubash

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $IRTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRTC

    DatePrice TargetRatingAnalyst
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    12/3/2024$86.00Equal Weight
    Wells Fargo
    10/4/2024$78.00Neutral
    Goldman
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    12/11/2023$110.00Neutral → Buy
    Citigroup
    7/19/2023$130.00Outperform
    Robert W. Baird
    2/7/2023$150.00Overweight
    Wells Fargo
    11/7/2022Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $IRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iRhythm upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00

    5/2/25 8:03:46 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Wells Fargo resumed coverage on iRhythm with a new price target

    Wells Fargo resumed coverage of iRhythm with a rating of Equal Weight and set a new price target of $86.00

    12/3/24 7:33:58 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on iRhythm with a new price target

    Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00

    10/4/24 7:40:56 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm's Zio LTCM Clinical Superiority

    In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total health care costs.Findings in a younger, commercially insured population build on data from the Medicare fee-for-service, population-based CAMELOT study, confirming the Zio LTCM service's value across patient populations and payer segments. SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced the publication of the real-world evidence study: Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evid

    8/18/25 8:05:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions

    Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a digital health leader focused on creating trusted solutions that detect, predict, and prevent disease, today announced a strategic partnership with Lucem Health, a leader in AI-driven early disease detection, to accelerate early identification of undiagnosed arrhythmias in patient po

    7/31/25 4:10:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces Second Quarter 2025 Financial Results

    SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA Recent Operational Highlights

    7/31/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/5/24 11:59:44 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/5/24 5:35:18 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

    4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/6/23 7:08:38 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    SEC Filings

    View All

    SEC Form 144 filed by iRhythm Technologies Inc.

    144 - iRhythm Technologies, Inc. (0001388658) (Subject)

    8/11/25 4:18:39 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by iRhythm Technologies Inc.

    144 - iRhythm Technologies, Inc. (0001388658) (Subject)

    8/5/25 4:51:34 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by iRhythm Technologies Inc.

    10-Q - iRhythm Technologies, Inc. (0001388658) (Filer)

    7/31/25 5:23:19 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Rosenbaum Marc Wade sold $35,918 worth of shares (226 units at $158.93), decreasing direct ownership by 2% to 10,879 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/12/25 4:39:08 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Director Talwalkar Abhijit Y exercised 5,312 shares at a strike of $10.71 and sold $839,381 worth of shares (5,312 units at $158.02) (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/12/25 4:38:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Patterson Chad sold $406,168 worth of shares (2,555 units at $158.97), decreasing direct ownership by 6% to 43,667 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/7/25 4:57:37 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Leadership Updates

    Live Leadership Updates

    View All

    iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

    iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

    2/29/24 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Derrick Sung Joins Aerin Medical as Chief Financial Officer

    A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

    11/20/23 9:00:00 AM ET
    $IRTC
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

    SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

    6/6/23 9:00:39 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Financials

    Live finance-specific insights

    View All

    iRhythm Technologies Announces Second Quarter 2025 Financial Results

    SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA Recent Operational Highlights

    7/31/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025

    SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading

    7/17/25 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces First Quarter 2025 Financial Results

    SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu

    5/1/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 12:54:21 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 9:52:49 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/7/24 4:05:49 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care